Table 2.

Overview of published clinical studies of MenACWY-CRM in children and adolescents

Age group	Immunogenicity among MenACWY-CRM recipients	Safety and tolerability among MenACWY-CRM recipients
Infants from 2 months of age*	60%–92% of two-dose and 81%–99% of three-dose recipients had protective hSBA titers (≥4)52	Most common reactions were injection site redness and irritability52
Infants from 6 months of age	86%–100% of two-dose recipients had protective hSBA titers (≥4)54	Most common reactions were injection site redness and irritability54
Toddlers	86%–100% of two-dose primed and 94%–100% of three-dose primed toddlers had protective hSBA titers (≥4)52	Most common reactions were injection site redness and irritability52
	65%–100% of unprimed toddlers had protective hSBA titers (≥4) after two doses54
Children aged 2–10 years	83%–95% of two-dose recipients had protective hSBA titers (≥4)56	Most common reactions were injection site pain, headache, and irritability56
Adolescents	75%–96% of adolescents had protective hSBA titers (≥4)58,59	Most common reactions were injection site pain and headache58,59

Note:

^*Used an adjuvant vaccine formulation.

Abbreviation: hSBA, human complement.